ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	11/9/2015 10:23:24 PM
	Read Replies (1) of 4474

Article in 'Oncogene' hints at pona activity in FGFR1 squamous cell lung cancer... PDGFRa inhibition may be key: Pona IC50 for PDGFRa is 1.1nM, more potent than FGFR1 (2.2nM) From the supplementary info: "Supplementary Table 3. Most of ponatinib sensitive cells are resistant to PD-173074 and NVP-BGJ398." 'Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression' nature.com Stay tuned for this Dr. Camidge video coming next week: Clinical Trial Spotlight: Identifying Lung Cancer Patients Who Respond to Ponatinib cancergrace.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next